FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
Go back to FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis| Regeneron (NASDAQ: REGN) | Delayed: 618.40 +5.90 (0.96%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $612.50 | 52 Week High | $592.36 | |||
| Open | $607.92 | 52 Week Low | $325.35 | |||
| Day High | $621.79 | P/E | 162.31 | |||
| Day Low | $607.92 | EPS | $3.81 | |||
| Volume | 365,219 | |||||
